GlassScriptPhysician profile
Vinod Valentine
NPI 1154740520
$4,546.19
in general payments reported to CMS, 2019-2025
18 companies · $578 in 2025
The $578 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $141 · 2021: $86.14 · 2022: $42.06 · 2023: $2,712 · 2024: $879 · 2025: $578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,148 · Travel and Lodging: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,147.70 |
| Travel and Lodging | $1,021.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,573.50 | 2020-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $818.45 | 2021-2025 | Valtoco |
| Acadia Pharmaceuticals INC | $496.41 | 2023-2025 | Daybue |
| Ucb, INC. | $445.45 | 2023-2024 | Briviact, Nayzilam, Fintepla |
| Supernus Pharmaceuticals, INC. | $245.24 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $215.05 | 2023 | Jornay Pm |
| Corium, LLC | $159.64 | 2023-2025 | Azstarys |
| Jazz Pharmaceuticals INC. | $129.78 | 2023-2024 | |
| Genzyme Corporation | $107.70 | 2019 | |
| Sk Life Science, INC. | $88.28 | 2023 | |
| Sumitomo Pharma America, INC. | $61.45 | 2023 | Aptiom |
| Tris Pharma INC | $55.81 | 2023-2025 | Onyda Xr, Dyanavel Xr |
| Immedica Pharma US, INC. | $55.37 | 2023 | |
| Sunovion Pharmaceuticals INC. | $22.26 | 2022 | |
| Biogen, INC. | $19.56 | 2023 | Spinraza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $19.42 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $18.51 | 2023 | Adzenys Xr-Odt |
| Eisai INC. | $14.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinod Valentine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.